重组人白介素-11对外周血造血干细胞移植后血小板恢复的影响

Effect of Recombinant Human Interleukin 11 on Recovery of Platelets after Peripheral Blood Hematopoietic Stem Cell Transplantation

本研究观察重组人白介素-11(rhIL-11)对恶性血液病患者在异基因外周血造血干细胞移植后血小板恢复的影响及其不良反应。20例接受同胞全相合异基因外周血造血干细胞移植术后的恶性血液病患者,随机分为"rhIL-11治疗组"和对照组。rhIL-11治疗组患者在移植术后6天(+6天)起应用rhIL-11 0.75mg/d,连续14天;对照组患者仅接受对症支持治疗,其间观察血小板计数由最低值恢复至>20×109/L和>50×109/L的时间并于移植后30天观察骨髓巨核细胞的数量。结果表明:rhIL-11治疗组患者血小板计数由最低值恢复至>20×109/L的时间平均为移植术后22.8天,对照组平均为移植术后27.3天,后者较治疗组延长4.5天(p<0.01)。治疗组患者血小板计数由最低值恢复至>50×109/L的时间平均为移植后24.5天,对照组平均为移植后35.3天,后者较治疗组延长9.6天(p<0.01)。移植术后30天时,对照组患者的骨髓巨核细胞总数及产板型数量分别为7.8个和4.2个,rhIL-11治疗组分别为15.6个和9.2个,均较对照组显著增加(p<0.01)。结论:造血干细胞移植后应用rhIL-11有加速血小板恢复的作用。

The aim of this study was to explore the effect of recombinant human interleukin 11 （rhIL-11） on platelet recovery after peripheral blood hematopoietic stem cell transplantation and its side-effects. 20 patients with hematologic malignancies treated by allogeneic peripheral blood stem cell transplantation （PBSCT） were randomly divided into test and control groups. The patients in test group were treated with rhIL-11 since the day 6 after PBSCT, while the patients in control group were given supporting treatment. The results showed that the average time of the platelet to recover to 20×10^9/L was 22.8 days in test group and 27.3 days in control group （p 〈0.01 ）. The average time for platelet to recover to 50×10^9/L was 25. 7 days in test group, and 32. 3 days in control group （ p 〈 0. 01 ）. The average number of megakaryocytes was 15.6 in test group, and 7.8 in control group on day 30 after PBSCT（p 〈0.01 ）. In conclusion, the rhIL-11 is able to accelerate platelet recovery after peripheral blood hematopoietic stem cell transplantation.